These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Is serologic screening necessary in the donor bloods for cytomegalovirus seronegative blood transfusion to risky patients?]. Mutlu B; Günlemez A; Türker G; Gökalp AS; Willke A Mikrobiyol Bul; 2008 Apr; 42(2):337-41. PubMed ID: 18697432 [TBL] [Abstract][Full Text] [Related]
6. CMV and blood transfusions. Roback JD Rev Med Virol; 2002; 12(4):211-9. PubMed ID: 12125013 [TBL] [Abstract][Full Text] [Related]
7. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative. Smith D; Lu Q; Yuan S; Goldfinger D; Fernando LP; Ziman A Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013 [TBL] [Abstract][Full Text] [Related]
8. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469 [TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection. Climent C; Vélez R; Capriles JA Bol Asoc Med P R; 1992 Jan; 84(1):31-3. PubMed ID: 1323967 [TBL] [Abstract][Full Text] [Related]
11. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Ziemann M; Krueger S; Maier AB; Unmack A; Goerg S; Hennig H Transfusion; 2007 Nov; 47(11):1972-83. PubMed ID: 17958525 [TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Winston DJ; Ho WG; Bartoni K; Champlin RE Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522 [TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection in a neonatal intensive care unit. Subsequent morbidity and mortality of seropositive infants. Griffin MP; O'Shea M; Brazy JE; Klein D; Koepke J; Malloy C; Wilfert CM J Perinatol; 1990 Mar; 10(1):43-5. PubMed ID: 2156031 [TBL] [Abstract][Full Text] [Related]
15. Congenital cytomegalovirus infection as a preventable complication of maternal transfusion. A case report. McGregor JA; Rubright G; Ogle JW J Reprod Med; 1990 Jan; 35(1):61-4. PubMed ID: 2153814 [TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India. Kothari A; Ramachandran VG; Gupta P; Singh B; Talwar V J Health Popul Nutr; 2002 Dec; 20(4):348-51. PubMed ID: 12659416 [TBL] [Abstract][Full Text] [Related]
17. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Ljungman P Br J Haematol; 2004 Apr; 125(2):107-16. PubMed ID: 15059132 [No Abstract] [Full Text] [Related]
18. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study. Moreno de la Higuera Díaz MA; Calvo Romero N; Sánchez-Fructuoso A; Conesa J; Marques Vidas M; Prats D; Barrientos Guzmán A Transplant Proc; 2007 Sep; 39(7):2231-2. PubMed ID: 17889147 [TBL] [Abstract][Full Text] [Related]